Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, presented results from a pre-clinical dose-optimization study conducted with a surrogate of its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at the 69th Scientific Sessions of the American Diabetes Association (ADA), which is continuing until June 9, 2009 in New Orleans, Louisiana. biotech industry
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis. The study was a multicenter, open-label clinical trial, which enrolled 55 patients. biotech industry
Five Positive Signs for Cash-Strapped Biotech Industry – Health .Are the deals and positive clinical-trial results a sign that the industry is emerging from the doldrums?
Czechs in America: The Czechs cheer for GMOs, America's mission .By some, including this , the study could be viewed as a wink and a nod to the powerful and aggressive agri-business biotech industry which has been attempting to make inroads into Europe, renowned for its fierce resistance to .
Silobreaker: AstraZeneca: ACS study met significant endpointAstroZeneca: Brilinta News Not a Panacea – Biotech Sector and Stocks Analysis from Seeking Alpha [05/11/2009]. Zacks.com submits: This morning, AstraZeneca (AZN) announced positive top-line results of its phase III 18600-patient PLATO .
